[1] 张荣昶,张帅,罗宇雄.阿托伐他汀钙片对稳定期慢性阻塞性肺疾病患者血清C反应蛋白,白介素-6 及肺功能的影响[J].转化医学杂志,2015,4(5):282.
[2] 刘温娟,梁蕊.COPD 患者血清hs-CRP,TNF-α和IL-6 的检测及其与肺功能和生活质量的相关性研究[J].临床肺科杂志,2013,18(4):616.
[3] FERRARI R,TANNI SE,CARAM LM,et al.Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease[J].Respir Res,2013,14(1):1.
[4] 杨培文,王群,利桂河,等.阿托伐他汀治疗稳定期重度COPD的临床研究[J].临床肺科杂志,2012,17(6):1041.
[5] HOWARD ML,VINCENT AH.Statin Effects on Exacerbation Rates,Mortality,and Inflammatory Markers in Patients with Chronic Obstructive Pulmonary Disease:A Review of Prospective Studies[J].Pharmacotherapy,2016,36(5):536.
[6] 王健宇.COPD患者联合应用BODE指数和SGRQ问卷的相关性研究[J].重庆医学,2012,41(36):3837.
[7] DECRAMER M,JANSSENS W.Chronic obstructive pulmonary disease and comorbidities[J].Lancet Respir Med,2013,1(1):73.
[8] 周敬凯,刘美,肇丽梅.他汀类药物在治疗慢性阻塞性肺疾病中的作用[J].药学服务与研究,2015,15(3):166.
[9] DENG ZC,ZHAO P,CAO C,et al.C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease[J].Exp Ther Med,2014,7(2):443.
[10]
[11] FIROUZJAHI A,MONADI M,KARIMPOOR F,et al.Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls:a case-control study from Iran[J].Inflammation,2013,36(5):1122.
[12] 周曦,严峻海,张柏膺.他汀类药物对慢性阻塞性肺疾病稳定期患者炎性因子影响作用研究[J].临床肺科杂志,2015,20(3):450.
[13] CELLI BR,LOCANTORE N,YATES J,et al.Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2012,185(10):1065.
[14] CAO C,WU Y,XU Z,et al.The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality:a systematic review and meta-analysis of observational research[J].Sci Rep,2015,5:16461.
[15] YAYAN J.No Significant Detectable Anti-infection Effects of Aspirin and Statins in Chronic Obstructive Pulmonary Disease[J].Int J Med Sci,2015,12(3):280.
[16] DIVO M,COTE C,DE TORRES JP,et al.Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2012,186(2):155.